Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

ELI-002 7PPositive

AI Analysis

Summary

Elicio Therapeutics announced a $15 million registered direct offering expected to close on July 6, 2026, with net proceeds designated for Phase 1 development of ELI-002 7P in metastatic PDAC and general corporate purposes.

Clinical Trial Data

Phase

Phase 1

Importance:6/10

Sentiment:

0.30

registered direct offeringcapital raiseKRAS-driven cancersimmunotherapyPhase 1 development

Related Companies

$ELTX

Read the original article

Published by GlobeNewswire Pharma on July 2, 2026 4:25 AM

Read Original